CS-121

Gene therapy / editing

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Severe Hypertriglyceridemia · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (3)
Familial Chylomicronemia Syndrome
Severe Hypertriglyceridemia
Other / comorbidity
NCT07371767 · Shanghai Jiao Tong University School of Medicine
2026-01-26 – 2041-01-31 · Hyperchylomicronemia
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 6 of them ahead of this one.

This drug's own stage for Familial Chylomicronemia Syndrome: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CS-121: this drugPhase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication
Olezarsen (Tryngolza)ApprovedRNA / oligonucleotideAPOC3Partial signal
NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53.
Plozasiran (Redemplo)ApprovedRNA / oligonucleotideAPOC3Partial signal
NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47)
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAReliable signal
NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5)
RBD5044
Phase 2(overall)
RNA / oligonucleotideAPOC3
not yet graded(overall)
No reviewed efficacy summary in this indication
RN0361
Phase 1/2(overall)
RNA / oligonucleotideAPOC3
not yet graded(overall)
No reviewed efficacy summary in this indication
Kylo-12
Phase 1(overall)
RNA / oligonucleotideAPOC3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow CS-121 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Familial Chylomicronemia SyndromeRecruiting
Est. primary completion 2026-12 · NCT07176923 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
Phase 1HyperchylomicronemiaRecruiting
Est. primary completion 2027-10-31 · NCT07371767 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 1Severe HypertriglyceridemiaNot yet recruiting
Est. primary completion 2028-03-15 · NCT07657780 · CT.gov ↗
What to watch

See the full readout calendar ↗